Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Yantai BeBetter Biotech
Guangzhou, Guangdong, Chinabebettermed.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead program BEBT-908 is a first-in-class PI3K/HDAC dual-target inhibitor, NDA accepted in China for r/r DLBCL. Demonstrated broad-spectrum anti-tumor activity, selected for Chinese national major drug innovation projects, and designated "Breakthrough Therapy"; other drugs in pipeline at Phase 2-3 in hematologic and solid tumors
- Therapeutic areas
- OncologyGastroenterology
- Modalities
- Small moleculesiRNAOligonucleotide
- Industry
- Biotech
Beyond the preview
Go deeper on Yantai BeBetter Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yantai BeBetter Biotech.